TransCode Therapeutics, Inc. (RNAZ) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.33
↓-100% vs avg
5yr avg: 568.45
30Y Low0.5·High14.1
ROE
↓
-833.5%
↑-83% vs avg
5yr avg: -455.6%
30Y Low-149%·High-81%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RNAZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
TransCode Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $5M | $24M | $23M | $5.6B | $10.5B | — | — | — |
| Enterprise Value | $-13062016 | $-13102781 | $18M | $21M | $5.6B | $10.5B | — | — | — |
| P/E Ratio → | -0.10 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.33 | 0.46 | — | 14.10 | 1743.07 | 516.16 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RNAZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
RNAZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -833.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -833.5% | -833.5% | — | -759.9% | -148.6% | -80.5% | — | — | — |
| ROA | -40.9% | -40.9% | -268.8% | -290.7% | -115.1% | -57.0% | -368.5% | -281.5% | -211.3% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -34.2% | -34.2% | -505.0% | -789.4% | -157.9% | -58.4% | -180.7% | -364.4% | -396.0% |
RNAZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.27 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.72 | — | -1.41 | -1.53 | -1.02 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -5203.81 | -5203.81 | -623.88 | -330.78 | -1.00 | -70.98 | -4.94 | -2.87 | — |
Net cash position: cash ($18M) exceeds total debt ($0)
RNAZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
TransCode Therapeutics, Inc.'s current ratio of 6.29x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.28x to 6.29x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.29 | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 | 2.05 | 3.25 | 1.82 |
| Quick Ratio | 6.29 | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 | 2.05 | 3.25 | 1.82 |
| Cash Ratio | 5.10 | 5.10 | 2.10 | 0.79 | 1.15 | 8.22 | 2.05 | 3.25 | 1.81 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
RNAZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
TransCode Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $689713 | $356115 | $5424 | $16221 | $10532 | $7979 | $6407 | $192 |
Peer Comparison
Compare RNAZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RNAZYou | $5M | -0.1 | — | — | — | — | -833.5% | — | — |
 ARWR | $12B | -6721.3 | 95.6 | 73.6 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 MRNA | $24B | -8.2 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 STRO | $307M | -1.4 | — | — | 92.9% | -102.4% | — | — | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -43.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $274M | -1.6 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 AVXL | $235M | -4.7 | — | — | — | — | -43.1% | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RNAZ — Frequently Asked Questions
Quick answers to the most common questions about buying RNAZ stock.
What is TransCode Therapeutics, Inc.'s P/E ratio?
TransCode Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is TransCode Therapeutics, Inc.'s ROE?
TransCode Therapeutics, Inc.'s return on equity (ROE) is -833.5%. The historical average is -114.6%.
Is RNAZ stock overvalued?
Based on historical data, TransCode Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.